 Dr. Yuede will present the preclinical Alzheimers disease mouse model data for exploring HT-ALZ for the treatment of Alzheimers disease NEW YORK , April 12, 2022 PRNewswire -- Hoth Therapeutics, Inc. NASDAQ: HOTH, a patient-focused biopharmaceutical company, today announced acceptance to present the preclinical Alzheimers disease mouse model data of HT-ALZ at the Alzheimers Association International Conference taking place July 31 August 4, 2022 in San Diego, California. The presentation will include results from cognitive and behavioral studies currently underway with HT-ALZ using an APPPS1 mouse model. 